olmesartan medoxomil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic)	1985	144689-63-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: olmesartan medoxomil olmetec CS-866 CS866	Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Molecular weight: 558.60 Formula: C29H30N6O6 CLOGP: 3.54 LIPINSKI: 2 HAC: 12 HDO: 2 TPSA: 154.34 ALOGS: -4.88 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

olmesartan medoxomil
olmetec
CS-866
CS866

Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle.

Molecular weight: 558.60
Formula: C29H30N6O6
CLOGP: 3.54
LIPINSKI: 2
HAC: 12
HDO: 2
TPSA: 154.34
ALOGS: -4.88
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.02 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	26 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
April 25, 2002	FDA	DAIICHI SANKYO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sprue-like enteropathy	661.67	11.25	137	34437	606	63453842
Malabsorption	385.47	11.25	126	34448	3946	63450502
Intestinal villi atrophy	153.85	11.25	34	34540	216	63454232
Colitis microscopic	116.07	11.25	69	34505	9270	63445178
Hyperkalaemia	93.89	11.25	131	34443	54072	63400376
Dehydration	83.39	11.25	245	34329	173109	63281339
Acute kidney injury	81.46	11.25	321	34253	263094	63191354
Hyponatraemia	76.10	11.25	180	34394	111720	63342728
Renal failure	75.45	11.25	185	34389	117467	63336981
Systemic lupus erythematosus	74.93	11.25	12	34562	208906	63245542
Device related thrombosis	73.87	11.25	30	34544	1755	63452693
Blood pressure increased	70.38	11.25	221	34353	161841	63292607
Wound	69.62	11.25	5	34569	163258	63291190
Diarrhoea	64.72	11.25	633	33941	714733	62739715
Off label use	56.60	11.25	184	34390	674278	62780170
Coeliac disease	55.52	11.25	50	34524	12747	63441701
Infusion related reaction	54.68	11.25	33	34541	245488	63208960
Drug intolerance	54.11	11.25	53	34521	308608	63145840
Hypertensive crisis	51.62	11.25	52	34522	15234	63439214
Renal impairment	51.47	11.25	134	34440	88221	63366227
Glossodynia	50.83	11.25	17	34557	178859	63275589
Maternal exposure during pregnancy	49.81	11.25	29	34545	220033	63234415
Lower respiratory tract infection	48.79	11.25	7	34567	132300	63322148
Blood pressure inadequately controlled	47.26	11.25	31	34543	4947	63449501
Blood immunoglobulin M increased	46.58	11.25	19	34555	1124	63453324
Chronic gastritis	46.12	11.25	25	34549	2816	63451632
Therapeutic product effect decreased	45.83	11.25	24	34550	193163	63261285
Oligohydramnios	44.84	11.25	33	34541	6333	63448115
Drug ineffective	44.82	11.25	360	34214	1044405	62410043
Hepatic enzyme abnormal	44.72	11.25	33	34541	6359	63448089
Bradycardia	44.65	11.25	113	34461	73114	63381334
Blood immunoglobulin A decreased	43.98	11.25	19	34555	1298	63453150
Hypotension	43.85	11.25	276	34298	272328	63182120
Microvillous inclusion disease	43.35	11.25	8	34566	16	63454432
Synovitis	43.20	11.25	24	34550	186894	63267554
Treatment failure	42.59	11.25	28	34546	199015	63255433
Gallbladder polyp	42.35	11.25	16	34558	771	63453677
Blood immunoglobulin G increased	41.20	11.25	22	34552	2405	63452043
Completed suicide	41.11	11.25	14	34560	145659	63308789
Hypertensive emergency	40.45	11.25	20	34554	1862	63452586
Cerebral infarction	40.24	11.25	57	34517	23836	63430612
Swelling	36.99	11.25	58	34516	275320	63179128
Hypokalaemia	35.71	11.25	131	34443	103673	63350775
Weight decreased	35.44	11.25	265	34309	276533	63177915
Discomfort	35.19	11.25	24	34550	167350	63287098
Blood urea increased	34.58	11.25	56	34518	26323	63428125
Collagen disorder	34.32	11.25	10	34564	211	63454237
Blood pressure decreased	34.22	11.25	95	34479	64927	63389521
Blood creatinine increased	33.77	11.25	115	34459	87729	63366719
Metabolic acidosis	32.25	11.25	74	34500	44995	63409453
Pain	32.20	11.25	254	34320	740374	62714074
Gastritis	32.12	11.25	66	34508	37237	63417211
Product use issue	31.99	11.25	44	34530	220476	63233972
Alopecia	31.87	11.25	87	34487	337449	63116999
Asthenia	31.87	11.25	334	34240	383270	63071178
Helicobacter infection	31.77	11.25	6	34568	92779	63361669
Syncope	31.44	11.25	137	34437	117248	63337200
Toxicity to various agents	31.40	11.25	54	34520	247196	63207252
Rheumatic disorder	31.30	11.25	20	34554	3052	63451396
Renal disorder	30.37	11.25	60	34514	32914	63421534
Pancreatic toxicity	29.07	11.25	6	34568	26	63454422
Blood glucose increased	29.05	11.25	106	34468	83650	63370798
Dizziness	28.39	11.25	358	34216	429567	63024881
Arthropathy	28.27	11.25	53	34521	234739	63219709
Contraindicated product administered	28.13	11.25	47	34527	217601	63236847
Heart rate irregular	27.24	11.25	46	34528	22375	63432073
Cardiac failure congestive	27.17	11.25	111	34463	92322	63362126
Hypocalvaria	26.90	11.25	6	34568	40	63454408
Lymphocytic infiltration	26.74	11.25	12	34562	898	63453550
Abdominal discomfort	26.49	11.25	88	34486	320797	63133651
Gravitational oedema	26.39	11.25	13	34561	1201	63453247
Enteritis	25.82	11.25	27	34547	8259	63446189
Intentional product use issue	24.73	11.25	20	34554	127872	63326576
Nail disorder	23.33	11.25	32	34542	12983	63441465
Multiple fractures	23.21	11.25	26	34548	8592	63445856
Joint swelling	23.03	11.25	96	34478	327570	63126878
Musculoskeletal stiffness	22.81	11.25	41	34533	184577	63269871
Exposure during pregnancy	22.59	11.25	31	34543	155516	63298932
Autoimmune enteropathy	22.40	11.25	4	34570	6	63454442
Diverticulum	22.28	11.25	30	34544	11961	63442487
Putamen haemorrhage	22.08	11.25	7	34567	198	63454250
General physical health deterioration	22.07	11.25	48	34526	201354	63253094
Enterocolitis	21.67	11.25	24	34550	7834	63446614
Gastrooesophageal reflux disease	21.45	11.25	106	34468	95533	63358915
Impaired healing	21.15	11.25	15	34559	102527	63351921
Product use in unapproved indication	21.04	11.25	41	34533	179039	63275409
Hypersensitivity	21.03	11.25	85	34489	292600	63161848
Spleen congestion	20.94	11.25	6	34568	119	63454329
Hepatic enzyme increased	20.73	11.25	50	34524	202278	63252170
Blood creatine phosphokinase increased	20.71	11.25	49	34525	30381	63424067
Eye disorder	20.55	11.25	41	34533	22644	63431804
Azotaemia	20.45	11.25	18	34556	4453	63449995
Renal impairment neonatal	20.36	11.25	5	34569	53	63454395
Oesophagitis	19.86	11.25	32	34542	14976	63439472
Skin exfoliation	19.80	11.25	60	34514	43042	63411406
Condition aggravated	19.79	11.25	133	34441	402084	63052364
Coronary artery disease	19.76	11.25	50	34524	32327	63422121
Prerenal failure	19.70	11.25	12	34562	1684	63452764
Eosinophil count	19.55	11.25	3	34571	0	63454448
Chronic kidney disease	18.84	11.25	61	34513	45337	63409111
Death	18.82	11.25	123	34451	374258	63080190
Burn oesophageal	18.25	11.25	6	34568	191	63454257
Glaucoma	18.13	11.25	35	34539	18870	63435578
Large intestine polyp	17.65	11.25	22	34552	8135	63446313
Diverticulitis	17.18	11.25	54	34520	39503	63414945
Anti-transglutaminase antibody increased	17.01	11.25	3	34571	4	63454444
Hypoalbuminaemia	16.77	11.25	26	34548	11779	63442669
Distributive shock	16.62	11.25	10	34564	1373	63453075
Inappropriate antidiuretic hormone secretion	16.54	11.25	30	34544	15432	63439016
Alanine aminotransferase increased	15.98	11.25	104	34470	103666	63350782
Gastritis erosive	15.89	11.25	18	34556	6021	63448427
Hyperuricaemia	15.85	11.25	17	34557	5353	63449095
Electrolyte imbalance	15.52	11.25	34	34540	20042	63434406
Aortic valve calcification	15.50	11.25	7	34567	532	63453916
Confabulation	15.41	11.25	6	34568	314	63454134
Cystitis	15.34	11.25	65	34509	54926	63399522
Decreased appetite	15.24	11.25	206	34368	250846	63203602
Liver injury	15.12	11.25	7	34567	60513	63393935
Breast cancer metastatic	15.06	11.25	25	34549	11993	63442455
Infection	14.96	11.25	69	34505	229104	63225344
Hiatus hernia	14.94	11.25	35	34539	21559	63432889
Cerebrovascular accident	14.69	11.25	105	34469	107919	63346529
Fatigue	14.45	11.25	371	34203	887657	62566791
Renin increased	14.39	11.25	5	34569	189	63454259
Oedema peripheral	14.30	11.25	162	34412	189349	63265099
Abortion spontaneous	14.27	11.25	4	34570	47191	63407257
Blood aldosterone increased	14.17	11.25	5	34569	198	63454250
Blister	14.16	11.25	31	34543	129783	63324665
Product administration error	14.10	11.25	35	34539	22362	63432086
Febrile neutropenia	14.01	11.25	27	34547	118422	63336026
Hypertension neonatal	13.87	11.25	3	34571	17	63454431
Fibromyalgia	13.84	11.25	14	34560	80406	63374042
Hepatorenal failure	13.81	11.25	7	34567	687	63453761
Bradyphrenia	13.80	11.25	18	34556	6962	63447486
Cataract operation	13.76	11.25	16	34558	5506	63448942
Hepatic function abnormal	13.72	11.25	48	34526	37094	63417354
Atrial tachycardia	13.54	11.25	14	34560	4226	63450222
Therapeutic product effect incomplete	13.53	11.25	30	34544	125026	63329422
Ill-defined disorder	13.22	11.25	15	34559	81740	63372708
Aortic dissection	13.18	11.25	10	34564	2008	63452440
Acquired oesophageal web	13.17	11.25	5	34569	244	63454204
Myocardial infarction	12.95	11.25	96	34478	99797	63354651
Hernia	12.95	11.25	24	34550	12550	63441898
Atrial fibrillation	12.88	11.25	108	34466	116528	63337920
Iron deficiency anaemia	12.36	11.25	31	34543	19938	63434510
Mucosa vesicle	12.20	11.25	3	34571	32	63454416
Feeling abnormal	12.18	11.25	129	34445	148263	63306185
Purpura senile	12.15	11.25	6	34568	557	63453891
Gamma-glutamyltransferase	12.11	11.25	3	34571	33	63454415
Hypovolaemia	11.79	11.25	21	34553	10652	63443796
Withdrawal hypertension	11.70	11.25	4	34570	144	63454304
Drug-induced liver injury	11.57	11.25	48	34526	40174	63414274
COVID-19	11.54	11.25	28	34546	113075	63341373
Rhabdomyolysis	11.53	11.25	51	34523	43900	63410548
Renal artery stenosis	11.47	11.25	9	34565	1900	63452548
Chest pain	11.42	11.25	173	34401	215786	63238662
Hepatitis D	11.32	11.25	3	34571	44	63454404
Skin reaction	11.31	11.25	25	34549	14824	63439624

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sprue-like enteropathy	473.73	11.63	101	23278	412	34933140
Malabsorption	341.23	11.63	106	23273	2266	34931286
Gastrointestinal disorder	102.70	11.63	120	23259	33828	34899724
Intestinal villi atrophy	80.24	11.63	19	23360	135	34933417
Colitis microscopic	75.39	11.63	35	23344	2302	34931250
Renal impairment	64.65	11.63	173	23206	94340	34839212
Death	60.42	11.63	109	23270	397940	34535612
Coeliac disease	50.81	11.63	19	23360	721	34932831
Toxicity to various agents	48.31	11.63	38	23341	200324	34733228
Off label use	48.01	11.63	134	23245	419390	34514162
Right atrial hypertrophy	45.72	11.63	18	23361	787	34932765
Syncope	42.35	11.63	146	23233	91305	34842247
Blood pressure increased	41.98	11.63	142	23237	87960	34845592
Hepatic function abnormal	38.51	11.63	89	23290	44274	34889278
Dehydration	38.14	11.63	180	23199	129789	34803763
Hypotension	38.06	11.63	266	23113	221383	34712169
Fractional exhaled nitric oxide increased	37.39	11.63	17	23362	1065	34932487
Diarrhoea	36.79	11.63	410	22969	389502	34544050
Hyperkalaemia	36.78	11.63	116	23263	69273	34864279
Bronchial wall thickening	36.55	11.63	18	23361	1350	34932202
Weight decreased	35.35	11.63	220	23159	176081	34757471
Blood pressure decreased	34.88	11.63	94	23285	51421	34882131
Right ventricular hypertrophy	34.60	11.63	18	23361	1516	34932036
Bronchial secretion retention	34.58	11.63	18	23361	1518	34932034
Drug ineffective	32.79	11.63	176	23203	456575	34476977
Dizziness	30.59	11.63	250	23129	218271	34715281
Aortic valve stenosis	29.89	11.63	20	23359	2683	34930869
Drug abuse	29.05	11.63	15	23364	99081	34834471
Hyperkinetic heart syndrome	28.39	11.63	8	23371	120	34933432
Pulmonary function test abnormal	28.11	11.63	19	23360	2591	34930961
Pulmonary hypoplasia	27.83	11.63	11	23368	486	34933066
Cerebral infarction	27.11	11.63	58	23321	27397	34906155
Interstitial lung disease	26.60	11.63	100	23279	65182	34868370
Gastrooesophageal reflux disease	26.47	11.63	70	23309	37854	34895698
Neutropenia	26.40	11.63	40	23339	156738	34776814
Brain natriuretic peptide increased	25.99	11.63	25	23354	5634	34927918
Gastrointestinal erosion	25.94	11.63	10	23369	413	34933139
Obstructive airways disorder	25.77	11.63	41	23338	15453	34918099
Obstruction	25.09	11.63	18	23361	2701	34930851
Hypertensive crisis	24.89	11.63	30	23349	8721	34924831
Microvillous inclusion disease	24.86	11.63	8	23371	192	34933360
Sensation of foreign body	24.71	11.63	18	23361	2765	34930787
Completed suicide	24.41	11.63	18	23361	98150	34835402
Plantar fasciitis	24.23	11.63	16	23363	2100	34931452
Myoglobin blood increased	23.38	11.63	18	23361	3005	34930547
Chest X-ray abnormal	23.23	11.63	21	23358	4377	34929175
Hyperuricaemia	21.95	11.63	27	23352	8016	34925536
Hypokalaemia	21.94	11.63	87	23292	58127	34875425
Acute kidney injury	21.50	11.63	304	23075	304684	34628868
Lip oedema	21.18	11.63	16	23363	2597	34930955
Gout	20.55	11.63	42	23337	19211	34914341
Anaplastic astrocytoma	19.97	11.63	6	23373	114	34933438
Erosive duodenitis	19.65	11.63	13	23366	1711	34931841
Coronary artery occlusion	19.61	11.63	30	23349	10932	34922620
Atrial fibrillation	19.28	11.63	144	23235	122249	34811303
Tropical sprue	18.93	11.63	3	23376	0	34933552
Papillary renal cell carcinoma	18.84	11.63	7	23372	261	34933291
Loss of consciousness	18.34	11.63	106	23273	82561	34850991
Intestinal intraepithelial lymphocytes increased	17.91	11.63	6	23373	164	34933388
Sleep apnoea syndrome	17.88	11.63	41	23338	20280	34913272
Hypertensive emergency	17.35	11.63	10	23369	1030	34932522
Ischaemic enteritis	17.34	11.63	4	23375	25	34933527
Diastolic dysfunction	17.15	11.63	21	23358	6206	34927346
Treatment failure	17.09	11.63	5	23374	46692	34886860
Haemorrhoids	17.00	11.63	33	23346	14542	34919010
Product use in unapproved indication	17.00	11.63	33	23346	117466	34816086
Hypertension	16.89	11.63	152	23227	136291	34797261
Febrile neutropenia	16.86	11.63	42	23337	136807	34796745
Oligohydramnios	16.68	11.63	7	23372	361	34933191
Infective exacerbation of chronic obstructive airways disease	16.50	11.63	12	23367	1839	34931713
Renal failure	16.45	11.63	146	23233	130411	34803141
Lymphangiectasia intestinal	16.39	11.63	3	23376	4	34933548
Coronary artery disease	15.70	11.63	69	23310	48236	34885316
Chronic gastritis	15.46	11.63	11	23368	1629	34931923
Collagen disorder	15.09	11.63	5	23374	132	34933420
Intervertebral disc degeneration	15.08	11.63	20	23359	6397	34927155
Decreased appetite	14.70	11.63	173	23206	166219	34767333
Histology abnormal	14.48	11.63	6	23373	300	34933252
Jealous delusion	14.34	11.63	6	23373	307	34933245
Atrophy	14.31	11.63	9	23370	1086	34932466
Cardiac failure congestive	14.27	11.63	100	23279	83170	34850382
Disease progression	14.24	11.63	32	23347	108045	34825507
Kidney small	14.13	11.63	4	23375	61	34933491
Intestinal ulcer perforation	13.92	11.63	3	23376	13	34933539
Full blood count abnormal	13.57	11.63	35	23344	18633	34914919
Hypovolaemia	13.42	11.63	23	23356	9211	34924341
Heart sounds abnormal	13.38	11.63	8	23371	882	34932670
Insulin-like growth factor increased	13.27	11.63	9	23370	1234	34932318
Prerenal failure	13.12	11.63	11	23368	2073	34931479
Rectal ulcer haemorrhage	13.12	11.63	4	23375	80	34933472
Transient aphasia	12.86	11.63	6	23373	399	34933153
Blood pressure inadequately controlled	12.77	11.63	12	23367	2628	34930924
Pancytopenia	12.68	11.63	28	23351	95129	34838423
Enterocolitis viral	12.55	11.63	4	23375	93	34933459
General physical health deterioration	12.45	11.63	44	23335	128225	34805327
Thrombocytopenia	12.40	11.63	58	23321	156189	34777363
Erectile dysfunction	12.33	11.63	36	23343	20601	34912951
Hospitalisation	12.22	11.63	12	23367	56890	34876662
Echocardiogram abnormal	12.08	11.63	8	23371	1055	34932497
Renal disorder	12.05	11.63	41	23338	25439	34908113
Palmar-plantar erythrodysaesthesia syndrome	11.71	11.63	31	23348	16764	34916788

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sprue-like enteropathy	1095.69	10.74	233	47091	1085	79695979
Malabsorption	557.03	10.74	179	47145	4853	79692211
Intestinal villi atrophy	225.52	10.74	53	47271	416	79696648
Colitis microscopic	184.28	10.74	101	47223	10667	79686397
Hyperkalaemia	121.27	10.74	232	47092	114166	79582898
Renal impairment	110.96	10.74	271	47053	157512	79539552
Dehydration	105.05	10.74	355	46969	247832	79449232
Diarrhoea	104.72	10.74	884	46440	879605	78817459
Gastrointestinal disorder	90.30	10.74	214	47110	121991	79575073
Off label use	84.92	10.74	267	47057	906948	78790116
Coeliac disease	82.39	10.74	62	47262	11289	79685775
Renal failure	80.23	10.74	282	47042	200686	79496378
Syncope	76.15	10.74	257	47067	179192	79517872
Toxicity to various agents	74.79	10.74	84	47240	421456	79275608
Hypertensive crisis	72.80	10.74	75	47249	20695	79676369
Acute kidney injury	71.02	10.74	539	46785	518865	79178199
Completed suicide	70.15	10.74	29	47295	245738	79451326
Blood pressure increased	69.73	10.74	279	47045	211081	79485983
Hypotension	69.46	10.74	473	46851	439844	79257220
Cerebral infarction	64.36	10.74	105	47219	45571	79651493
Chronic gastritis	63.70	10.74	36	47288	4032	79693032
Weight decreased	62.34	10.74	392	46932	354806	79342258
Microvillous inclusion disease	60.71	10.74	16	47308	209	79696855
Device related thrombosis	59.68	10.74	30	47294	2653	79694411
Drug ineffective	57.57	10.74	391	46933	1080522	78616542
Hypokalaemia	57.34	10.74	202	47122	143838	79553226
Hypertensive emergency	55.74	10.74	29	47295	2756	79694308
Blood pressure inadequately controlled	54.54	10.74	38	47286	6139	79690925
Blood pressure decreased	52.80	10.74	154	47170	99312	79597752
Death	52.65	10.74	167	47157	566347	79130717
Drug intolerance	49.73	10.74	50	47274	264069	79432995
Hepatic function abnormal	48.63	10.74	123	47201	72984	79624080
Collagen disorder	48.29	10.74	14	47310	265	79696799
Hyponatraemia	48.01	10.74	221	47103	177627	79519437
Pericarditis	46.94	10.74	4	47320	104232	79592832
Maternal exposure during pregnancy	44.29	10.74	13	47311	136525	79560539
Blood immunoglobulin G increased	42.92	10.74	25	47299	2964	79694100
Infusion related reaction	42.87	10.74	44	47280	230193	79466871
Hyperuricaemia	42.06	10.74	43	47281	11756	79685308
Blood immunoglobulin M increased	41.75	10.74	19	47305	1347	79695717
Right atrial hypertrophy	41.33	10.74	16	47308	755	79696309
Blood immunoglobulin A decreased	40.63	10.74	19	47305	1434	79695630
Systemic lupus erythematosus	40.28	10.74	11	47313	121138	79575926
Cardiac failure congestive	39.20	10.74	178	47146	142224	79554840
Lower respiratory tract infection	38.92	10.74	14	47310	129206	79567858
Gastrooesophageal reflux disease	37.92	10.74	142	47182	104104	79592960
Enteritis	37.86	10.74	45	47279	14538	79682526
Gallbladder polyp	37.46	10.74	16	47308	974	79696090
Renal disorder	36.95	10.74	79	47245	42026	79655038
Synovitis	36.64	10.74	22	47302	150712	79546352
Pain	36.63	10.74	256	47068	703546	78993518
Wound	36.00	10.74	12	47312	116167	79580897
Treatment failure	34.76	10.74	30	47294	170456	79526608
Bradycardia	34.05	10.74	165	47159	135392	79561672
Prerenal failure	33.24	10.74	23	47301	3675	79693389
Pemphigus	33.19	10.74	9	47315	99573	79597491
Obstruction	33.05	10.74	25	47299	4585	79692479
Hepatic enzyme abnormal	32.55	10.74	31	47293	7779	79689285
Gastritis	32.17	10.74	81	47243	47912	79649152
Tropical sprue	32.15	10.74	5	47319	0	79697064
Interstitial lung disease	31.17	10.74	141	47183	112459	79584605
Pulmonary function test abnormal	30.88	10.74	23	47301	4121	79692943
Therapeutic product effect decreased	30.85	10.74	31	47293	163832	79533232
Diverticulum	30.76	10.74	41	47283	14855	79682209
Autoimmune enteropathy	30.12	10.74	7	47317	52	79697012
Aortic valve stenosis	30	10.74	25	47299	5269	79691795
Right ventricular hypertrophy	29.80	10.74	16	47308	1621	79695443
Rheumatic disorder	29.23	10.74	20	47304	3138	79693926
Hyperkinetic heart syndrome	28.74	10.74	8	47316	130	79696934
Exposure during pregnancy	28.72	10.74	12	47312	101120	79595944
Dizziness	28.70	10.74	455	46869	525986	79171078
Intentional product use issue	28.38	10.74	29	47295	152083	79544981
Product use in unapproved indication	28.29	10.74	67	47257	250292	79446772
Chronic kidney disease	28.24	10.74	95	47229	66059	79631005
Glossodynia	28.18	10.74	13	47311	103324	79593740
Febrile neutropenia	27.57	10.74	60	47264	230939	79466125
Hypersensitivity	27.44	10.74	73	47251	262166	79434898
Blood urea increased	27.29	10.74	77	47247	48713	79648351
Swelling	26.95	10.74	55	47269	216656	79480408
Decreased appetite	26.86	10.74	316	47008	342102	79354962
Product use issue	26.30	10.74	53	47271	209769	79487295
Erosive duodenitis	25.97	10.74	16	47308	2101	79694963
Musculoskeletal stiffness	25.74	10.74	40	47284	174968	79522096
Lymphocytic infiltration	25.01	10.74	14	47310	1539	79695525
Blood creatinine increased	24.61	10.74	167	47157	154890	79542174
Hiatus hernia	24.33	10.74	47	47277	23265	79673799
Condition aggravated	24.23	10.74	186	47138	500938	79196126
General physical health deterioration	24.22	10.74	83	47241	275155	79421909
Asthenia	24.12	10.74	432	46892	511257	79185807
Enterocolitis	24.11	10.74	36	47288	14476	79682588
Drug abuse	24.10	10.74	37	47287	162654	79534410
Large intestine polyp	23.26	10.74	33	47291	12675	79684389
Bronchial wall thickening	22.74	10.74	16	47308	2625	79694439
Atrial fibrillation	22.41	10.74	197	47127	197689	79499375
Gout	22.37	10.74	47	47277	24702	79672362
Hypoalbuminaemia	22.30	10.74	43	47281	21254	79675810
Nail disorder	22.02	10.74	31	47293	11821	79685243
Neutropenia	21.92	10.74	92	47232	287618	79409446
Abdominal discomfort	21.79	10.74	76	47248	250651	79446413
Multiple fractures	21.22	10.74	25	47299	8001	79689063
Heart rate irregular	20.71	10.74	54	47270	32625	79664439
Muscle atrophy	20.31	10.74	29	47295	11203	79685861
Gravitational oedema	20.30	10.74	13	47311	1826	79695238
Aortic dissection	20.18	10.74	18	47306	4157	79692907
Discomfort	20.15	10.74	27	47297	125590	79571474
Hypovolaemia	20.11	10.74	37	47287	17654	79679410
Pulmonary hypoplasia	19.84	10.74	5	47319	54	79697010
Metabolic acidosis	19.68	10.74	99	47225	82430	79614634
Alopecia	19.52	10.74	71	47253	231284	79465780
Disease progression	19.52	10.74	51	47273	184311	79512753
Papillary renal cell carcinoma	19.48	10.74	7	47317	268	79696796
Joint swelling	19.19	10.74	97	47227	288549	79408515
Blood glucose increased	18.94	10.74	125	47199	114850	79582214
Exercise lack of	18.68	10.74	8	47316	490	79696574
Helicobacter infection	18.65	10.74	9	47315	69695	79627369
Anaplastic astrocytoma	18.55	10.74	6	47318	166	79696898
Putamen haemorrhage	18.40	10.74	8	47316	509	79696555
Skin exfoliation	18.34	10.74	73	47251	55027	79642037
Haemorrhoids	18.32	10.74	48	47276	29080	79667984
Drug ineffective for unapproved indication	18.30	10.74	4	47320	51234	79645830
Intestinal intraepithelial lymphocytes increased	18.28	10.74	6	47318	174	79696890
Breast cancer metastatic	18.26	10.74	24	47300	8578	79688486
Gastrointestinal erosion	18.13	10.74	10	47314	1068	79695996
Cerebral haemorrhage	18.08	10.74	75	47249	57598	79639466
Contraindicated product administered	17.91	10.74	42	47282	157496	79539568
Myocardial infarction	17.69	10.74	177	47147	183952	79513112
Fibromyalgia	17.69	10.74	8	47316	64332	79632732
Infective exacerbation of chronic obstructive airways disease	17.57	10.74	14	47310	2770	79694294
Coronary artery occlusion	17.37	10.74	32	47292	15283	79681781
Liver disorder	17.36	10.74	87	47237	72330	79624734
Arthropathy	17.26	10.74	51	47273	177060	79520004
Impaired healing	17.17	10.74	16	47308	87639	79609425
Bradyphrenia	17.12	10.74	26	47298	10614	79686450
Rhabdomyolysis	16.91	10.74	112	47212	103019	79594045
Diabetic nephropathy	16.87	10.74	14	47310	2933	79694131
Infection	16.77	10.74	80	47244	241632	79455432
Bronchial secretion retention	16.56	10.74	16	47308	4088	79692976
Gluten sensitivity	16.55	10.74	7	47317	416	79696648
Diverticulitis	16.22	10.74	62	47262	45874	79651190
Multiple allergies	16.04	10.74	25	47299	10435	79686629
Generalised oedema	15.87	10.74	40	47284	23669	79673395
Hypocalcaemia	15.71	10.74	65	47259	49859	79647205
COVID-19	15.65	10.74	45	47279	157629	79539435
Drug-induced liver injury	15.54	10.74	79	47245	66038	79631026
Ill-defined disorder	15.47	10.74	10	47314	65865	79631199
Chest X-ray abnormal	15.22	10.74	21	47303	7862	79689202
Blood potassium increased	15.21	10.74	45	47279	29230	79667834
Cataract operation	15.14	10.74	17	47307	5168	79691896
Oligohydramnios	15.10	10.74	14	47310	3398	79693666
Ileal ulcer	15.04	10.74	9	47315	1121	79695943
Platelet count decreased	14.95	10.74	179	47145	194485	79502579
Bradykinesia	14.89	10.74	21	47303	8022	79689042
Hepatic enzyme increased	14.78	10.74	57	47267	182553	79514511
Leukocyturia	14.76	10.74	11	47313	1972	79695092
Lymphocytosis	14.76	10.74	16	47308	4677	79692387
Jealous delusion	14.73	10.74	6	47318	324	79696740
Hypomagnesaemia	14.70	10.74	61	47263	46850	79650214
Histology abnormal	14.68	10.74	6	47318	327	79696737
Coronary artery disease	14.54	10.74	77	47247	65397	79631667
Anti-transglutaminase antibody increased	14.47	10.74	3	47321	12	79697052
Disturbance in attention	14.47	10.74	6	47318	50795	79646269
Lymphangiectasia intestinal	14.28	10.74	3	47321	13	79697051
Blood creatine phosphokinase increased	14.18	10.74	77	47247	66013	79631051
Presyncope	14.16	10.74	55	47269	40999	79656065
Diastolic dysfunction	14.08	10.74	24	47300	10787	79686277
Gastritis erosive	14.02	10.74	24	47300	10823	79686241
Lip oedema	13.99	10.74	18	47306	6298	79690766
Autoimmune hepatitis	13.85	10.74	25	47299	11758	79685306
Cystitis	13.82	10.74	65	47259	52667	79644397
Gastric cancer	13.79	10.74	23	47301	10156	79686908
Duodenitis	13.58	10.74	20	47304	7947	79689117
Chest pain	13.50	10.74	239	47085	282065	79414999
Intestinal ulcer perforation	13.46	10.74	3	47321	18	79697046
Hospitalisation	13.41	10.74	22	47302	94214	79602850
Leukopenia	13.29	10.74	31	47293	116482	79580582
Renal cyst haemorrhage	13.26	10.74	7	47317	685	79696379
Anaemia	13.03	10.74	351	46973	444664	79252400
Iron deficiency anaemia	12.90	10.74	39	47285	25633	79671431
Loss of consciousness	12.71	10.74	154	47170	167789	79529275
Transient aphasia	12.57	10.74	6	47318	474	79696590
Aortic valve calcification	12.56	10.74	7	47317	763	79696301
Cytokine release syndrome	12.48	10.74	3	47321	35995	79661069
Encephalopathy	12.39	10.74	13	47311	67384	79629680
Confabulation	12.36	10.74	6	47318	492	79696572
Diabetes mellitus inadequate control	12.32	10.74	37	47287	24227	79672837
Erectile dysfunction	12.28	10.74	27	47297	14637	79682427
Alanine aminotransferase increased	12.27	10.74	149	47175	162421	79534643
Hypertension	12.06	10.74	269	47055	330723	79366341
Sedation	12.02	10.74	8	47316	51887	79645177
Atrophy	12.01	10.74	10	47314	2104	79694960
Adverse drug reaction	11.99	10.74	13	47311	66379	79630685
Mucosa vesicle	11.94	10.74	3	47321	32	79697032
Blister	11.93	10.74	34	47290	119442	79577622
Polyp	11.91	10.74	19	47305	8088	79688976
Glaucoma	11.85	10.74	32	47292	19729	79677335
Oedema peripheral	11.85	10.74	213	47111	252075	79444989
Orthostatic hypotension	11.76	10.74	65	47259	56099	79640965
Azotaemia	11.62	10.74	19	47305	8257	79688807
Prescribed overdose	11.58	10.74	4	47320	37879	79659185
Metastases to liver	11.50	10.74	40	47284	28274	79668790
Ischaemic enteritis	11.42	10.74	4	47320	142	79696922
Inappropriate antidiuretic hormone secretion	11.42	10.74	38	47286	26275	79670789
Product substitution issue	11.36	10.74	32	47292	20224	79676840
Thalamus haemorrhage	11.33	10.74	9	47315	1773	79695291
Eye disorder	11.24	10.74	35	47289	23377	79673687
Normochromic normocytic anaemia	11.20	10.74	18	47306	7709	79689355
Acquired oesophageal web	11.16	10.74	5	47319	342	79696722
Palmar-plantar erythrodysaesthesia syndrome	11.11	10.74	44	47280	33090	79663974
Diverticulum intestinal	11.07	10.74	19	47305	8586	79688478
Gastrointestinal hypermotility	11.06	10.74	5	47319	349	79696715
Embolic stroke	11.03	10.74	18	47306	7808	79689256
Paranasal sinus haematoma	10.94	10.74	3	47321	46	79697018
Aspartate aminotransferase increased	10.87	10.74	128	47196	138513	79558551
Cell marker increased	10.84	10.74	6	47318	645	79696419
Duodenal ulcer haemorrhage	10.82	10.74	17	47307	7146	79689918
Heart sounds abnormal	10.78	10.74	8	47316	1425	79695639

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C09CA08	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN Angiotensin II receptor blockers (ARBs), plain
ATC	C09DA08	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and diuretics
ATC	C09DB02	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and calcium channel blockers
ATC	C09DX03	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs), other combinations
FDA MoA	N0000000070	Angiotensin 2 Receptor Antagonists
FDA EPC	N0000175561	Angiotensin 2 Receptor Blocker
MeSH PA	D047228	Angiotensin II Type 1 Receptor Blockers
MeSH PA	D057911	Angiotensin Receptor Antagonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:61016	angiotensin receptor antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	off-label use	48447003
Atrial fibrillation	off-label use	49436004	DOID:0060224
Diastolic heart failure	off-label use	418304008	DOID:9775
Nondiabetic Proteinuric Nephropathy	off-label use
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Secondary angle-closure glaucoma	contraindication	21571006
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006
Hyperuricemia	contraindication	35885006	DOID:1920
Angioedema	contraindication	41291007	DOID:1558
Hypokalemia	contraindication	43339004
Diabetes mellitus type 2	contraindication	44054006	DOID:9352
Low blood pressure	contraindication	45007003
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Hepatic failure	contraindication	59927004
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Chronic idiopathic constipation	contraindication	82934008
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Hypomagnesemia	contraindication	190855004
Acute pancreatitis	contraindication	197456007	DOID:2913
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006
Azotemia	contraindication	445009001
Severe Aortic Valve Stenosis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.25	acidic
pKa2	5.76	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Type-1 angiotensin II receptor	GPCR	P30556	AGTR1_HUMAN	ANTAGONIST	IC50	8.10		IUPHAR	CHEMBL
Type-1 angiotensin II receptor	GPCR		AGTR1_BOVIN		IC50	8.09		CHEMBL

External reference:

ID	Source
4021345	VUID
N0000179505	NUI
D01204	KEGG_DRUG
4021344	VANDF
4021345	VANDF
C0386393	UMLSCUI
CHEBI:31932	CHEBI
CHEBI:48416	CHEBI
OLM	PDB_CHEM_ID
CHEMBL1200692	ChEMBL_ID
D000068557	MESH_DESCRIPTOR_UI
C437965	MESH_SUPPLEMENTAL_RECORD_UI
7787	INN_ID
6M97XTV3HD	UNII
130881	PUBCHEM_CID
DB00275	DRUGBANK_ID
118463	RXNORM
16642	MMSL
245076	MMSL
d04801	MMSL
009634	NDDF
009635	NDDF
385540001	SNOMEDCT_US
412259001	SNOMEDCT_US
412260006	SNOMEDCT_US
C1098320	UMLSCUI
CHEMBL1516	ChEMBL_ID
8612	INN_ID
144689-24-7	SECONDARY_CAS_RN
158781	PUBCHEM_CID
591	IUPHAR_LIGAND_ID
8W1IQP3U10	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5002	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5002	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5003	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5003	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5004	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5004	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5005	TABLET, FILM COATED	20 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5005	TABLET, FILM COATED	20 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5006	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5006	TABLET, FILM COATED	40 mg	ORAL	ANDA	26 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2425	TABLET, FILM COATED	5 mg	ORAL	ANDA	31 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2425	TABLET, FILM COATED	5 mg	ORAL	ANDA	31 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2426	TABLET, FILM COATED	20 mg	ORAL	ANDA	31 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2426	TABLET, FILM COATED	20 mg	ORAL	ANDA	31 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2427	TABLET, FILM COATED	40 mg	ORAL	ANDA	31 sections
OLMESARTAN MEDOXOMIL	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2427	TABLET, FILM COATED	40 mg	ORAL	ANDA	31 sections
Benicar	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0860	TABLET, FILM COATED	5 mg	ORAL	NDA	32 sections
Benicar	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0860	TABLET, FILM COATED	5 mg	ORAL	NDA	32 sections
Benicar	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0861	TABLET, FILM COATED	20 mg	ORAL	NDA	32 sections
Benicar	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0861	TABLET, FILM COATED	20 mg	ORAL	NDA	32 sections
Benicar	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0862	TABLET, FILM COATED	40 mg	ORAL	NDA	32 sections
Benicar	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0862	TABLET, FILM COATED	40 mg	ORAL	NDA	32 sections
Benicar HCT	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0863	TABLET, FILM COATED	20 mg	ORAL	NDA	26 sections
Benicar HCT	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0863	TABLET, FILM COATED	20 mg	ORAL	NDA	26 sections
Benicar HCT	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0864	TABLET, FILM COATED	40 mg	ORAL	NDA	26 sections
Benicar HCT	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0864	TABLET, FILM COATED	40 mg	ORAL	NDA	26 sections
Benicar HCT	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0865	TABLET, FILM COATED	40 mg	ORAL	NDA	26 sections
Benicar HCT	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0865	TABLET, FILM COATED	40 mg	ORAL	NDA	26 sections
Azor	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0870	TABLET, FILM COATED	20 mg	ORAL	NDA	26 sections
Azor	HUMAN PRESCRIPTION DRUG LABEL	2	0713-0870	TABLET, FILM COATED	20 mg	ORAL	NDA	26 sections